KalVista Pharmaceuticals recently entered a definitive merger agreement with Chiesi Farmaceutici S.p.A. that includes a $27 cash per share tender offer, underscored by a significant $66.4 million termination fee. This deal marks a pivotal strategic shift against the backdrop of EKTERLY’s emerging commercial footprint as a pediatric first-line therapy for hereditary angioedema (HAE), supported by positive Phase 3 data. While the merger promises expanded resources and international reach, it introduces regulatory and integration uncertainties. KalVista’s focused pipeline and orphan disease niche underpin its market differentiation, but execution risks and competitive pressures prevail.